Equities analysts expect Nevro Corp (NYSE:NVRO) to report ($0.81) earnings per share for the current quarter, according to Zacks. Five analysts have provided estimates for Nevro’s earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.97). Nevro posted earnings of ($0.37) per share during the same quarter last year, which suggests a negative year over year growth rate of 118.9%. The company is scheduled to report its next earnings report on Monday, November 4th.
On average, analysts expect that Nevro will report full year earnings of ($3.87) per share for the current year, with EPS estimates ranging from ($4.26) to ($3.36). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.83) per share, with EPS estimates ranging from ($3.81) to ($1.35). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover Nevro.
Nevro (NYSE:NVRO) last released its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.02). Nevro had a negative return on equity of 39.62% and a negative net margin of 24.51%. The company had revenue of $93.60 million for the quarter, compared to analyst estimates of $88.40 million. During the same quarter last year, the company earned ($0.35) EPS. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis.
Several research firms recently weighed in on NVRO. Zacks Investment Research upgraded shares of Nevro from a “sell” rating to a “hold” rating and set a $67.00 price target for the company in a research report on Tuesday. Northland Securities set a $65.00 price target on shares of Nevro and gave the stock a “hold” rating in a research report on Friday, August 9th. Morgan Stanley set a $76.00 price target on shares of Nevro and gave the stock a “buy” rating in a research report on Friday, August 9th. ValuEngine upgraded shares of Nevro from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 24th. Finally, JMP Securities increased their price objective on shares of Nevro from $70.00 to $90.00 and gave the company a “market outperform” rating in a report on Monday. Two analysts have rated the stock with a sell rating, four have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Nevro currently has a consensus rating of “Hold” and an average price target of $62.91.
In other news, Director Kevin C. Oboyle purchased 1,675 shares of the company’s stock in a transaction dated Wednesday, June 5th. The stock was acquired at an average price of $60.00 per share, with a total value of $100,500.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Elizabeth H. Weatherman purchased 2,460 shares of the company’s stock in a transaction dated Friday, June 7th. The stock was purchased at an average cost of $60.99 per share, with a total value of $150,035.40. The disclosure for this purchase can be found here. 7.60% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Rice Hall James & Associates LLC grew its stake in shares of Nevro by 206.2% in the 1st quarter. Rice Hall James & Associates LLC now owns 33,135 shares of the medical equipment provider’s stock valued at $2,071,000 after buying an additional 22,312 shares during the period. Norges Bank purchased a new stake in shares of Nevro in the 4th quarter valued at approximately $36,675,000. Edmond DE Rothschild Holding S.A. grew its stake in shares of Nevro by 31.0% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 138,290 shares of the medical equipment provider’s stock valued at $8,645,000 after buying an additional 32,700 shares during the period. Private Advisors LLC purchased a new stake in shares of Nevro in the 1st quarter valued at approximately $450,000. Finally, Spark Investment Management LLC grew its stake in shares of Nevro by 144.9% in the 1st quarter. Spark Investment Management LLC now owns 403,400 shares of the medical equipment provider’s stock valued at $25,216,000 after buying an additional 238,700 shares during the period.
Shares of NVRO traded down $2.04 during mid-day trading on Thursday, hitting $80.79. 812,000 shares of the company were exchanged, compared to its average volume of 578,017. Nevro has a 1-year low of $34.75 and a 1-year high of $83.57. The company has a debt-to-equity ratio of 0.83, a quick ratio of 4.87 and a current ratio of 6.30. The company has a 50 day moving average of $65.88 and a 200-day moving average of $59.24. The stock has a market cap of $2.45 billion, a price-to-earnings ratio of -49.26 and a beta of 0.29.
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Featured Story: Strike Price
Get a free copy of the Zacks research report on Nevro (NVRO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.